

## Narimon Honarpour, MD, PhD

Email: [narimonh@amgen.com](mailto:narimonh@amgen.com)

Phone: (805) 341-0516

### Summary

A physician-scientist with significant industry experience, having managed drug development in cardiovascular & metabolic disease, inflammation and oncology as well as platform functions with responsibilities across all phases of development. My focus is on leading multidisciplinary teams to advance the pipeline and creating an environment that enables success.

### Professional Experience

#### **Amgen Inc.**

**2021-current**

#### **General Medicine Head & JAPAC Global Development Head and Vice President**

- Leading General Medicine therapeutic area (cardiometabolic, neuroscience, bone, nephrology) and cross-functional group of applied scientists in clinical pharmacology, clinical immunology
- Responsibilities over all early and late development programs in cardiometabolic, inflammation, neurosciences and nephrology
- Responsibility for Asia-Pacific clinical development activities across pipeline
- Managing ~140 staff and General Medicine Portfolio Governance (~\$200M annual budget)

**2019-2021**

#### **Translational Medicine Head and Vice President**

- Leading a cross-functional group of physicians and scientists that advance early pipeline assets to late-phase development across all therapeutic areas
- Responsibilities over all phase 1 development, clinical pharmacology, clinical biomarker & diagnostics and clinical immunology functions
- Managing ~30 Phase 1 assets, 140 staff

**2018-2019**

#### **Global Product General Manager**

- Led early-phase product teams in inflammation (lupus, rheumatoid arthritis, ulcerative colitis)
- Managed long-term product strategy, resourcing and budget for clinical-stage assets

**2017-2018**

#### **Global Product Area Lead and Executive Medical Director**

- Managed clinical development strategy for 3 heart failure products: Corlanor<sup>®</sup>, Omecamtiv Mecarbil (phase 3), AMG 986 (phase 1)
- Coordination of clinical development strategy for Omecamtiv Mecarbil with partners across 3 organizations

**2015-2017**

#### **Global Development Lead and Executive Medical Director**

- Development of phase 3 program strategy for Omecamtiv Mecarbil
- Led end-of-phase 2 transition and activities for Omecamtiv Mecarbil
- Regulatory engagement with FDA (Type A, B and C meetings); end-of-phase 2 meetings with EMA, Health Canada and PMDA
- Drug monitoring medical device development experience

**2013-2015**

#### **Clinical Research Medical Director**

- Phase 3 CV outcomes trial design, implementation, and monitoring
- Regulatory filing experience for Repatha<sup>®</sup> in US, Europe and Japan
- Repatha<sup>®</sup> FDA EMDAC triage team lead
- Corlanor<sup>®</sup> FDA CRDAC preparatory experience
- Breakthrough and Orphan drug therapy application experience

**2011-2013**

#### **Senior Medical Scientist**

- Repatha phase 2 and 3 clinical trial design, monitoring
- Moderated Advisory boards/investigator meetings
- Collaboration with global health economics, payer network and observational research teams

**Narimon Honarpour, MD, PhD**

Email: [narimonh@amgen.com](mailto:narimonh@amgen.com)

Phone: (805) 341-0516

### **Professional Experience (continued)**

- 2010-2011 Clinical Instructor; UCLA Division of Cardiology; Los Angeles, CA**
- Inpatient and outpatient cardiologist
  - Independently funded lab PI (stem cell differentiation into cardiovascular tissue)
- 2010-2011 Visiting Faculty; California Institute of Technology; Pasadena, CA**

### **External Committee Memberships:**

Executive Committee Member, FNIH Accelerating Medicine Partnership Program  
Executive Leadership Council, Ventura County American Heart Association Chapter

### **Community Service**

**2019-2022** Board Member; Casa Pacifica Centers For Children & Families; Camarillo, CA

### **Training and Education**

- 2006-2010 Postdoctoral Fellow; Caltech Pasadena, CA  
2005-2010 Clinical Fellowship in Cardiology; UCLA Los Angeles, CA  
2003-2005 Residency in Internal Medicine; UCLA Los Angeles, CA  
1996-2003 MD, PhD; University of Texas Southwestern Medical Center; Dallas, TX  
1992-1996 BS Chemical Engineering; University of Texas; Austin, TX

### **Selected, Peer-Reviewed Publications**

- Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. *New England Journal of Medicine*. 2020; Nov 13 online ahead of print.
- Wirtz HS, Sheer R, **Honarpour N**, Casbeer AW, Simmons JD, Kurtz CE, Pasquale MK, Globe G. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. *Journal of the American Heart Association*. 2020; 9(16):e015042.
- Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Buchele G, Varin C, Kurtz CE, Malik FI, **Honarpour N**. Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. *JACC Heart Failure*. 2020;8(4):329-40.
- Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, **Honarpour N**, Velazquez EJ. Association Between Systolic Ejection Time and Outcomes in Heart Failure by Ejection Fraction. *European Journal of Heart Failure*. 2020; 22(7):1174-82.
- Giugliano RP, Mach F, Zavitz Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS., Robinson JG, **Honarpour N**, Wasserman SM, Ott BR. Cognitive Function in a Randomized Trial of Evolocumab. *New England Journal of Medicine*. 2017;377:633-643.
- Sabatine MS, Giugliano RP, Keech A, **Honarpour N**, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine*. 2017;376:1713-1722.
- Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, **Honarpour N**. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a Phase 2, Pharmacokinetic, Randomised, Placebo-controlled Trial. *Lancet*. 2016; 388:2895-2903.
- Sabatine MS, Giugliano RP, Keech A, **Honarpour N**, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR. Rationale and Design of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk Trial. *American Heart Journal*. 2016; 173:94-101.
- Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, **Honarpour N**, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA. PCSK9 Inhibition-mediated Reduction in Lp(a) with Evolocumab: an Analysis of 10 Clinical Trials and the LDL Receptor's Role. *Journal of Lipid Research*. 2016;57:1086-96
- Raal FJ, **Honarpour N**, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; Inhibition of PCSK9 with Evolocumab in Homozygous Familial Hypercholesterolaemia (TESLA Part B): a Randomised, Double-blind, Placebo-controlled Trial. *Lancet*. 2015;385:341-50.

**Narimon Honarpour, MD, PhD**

Email: [narimonh@amgen.com](mailto:narimonh@amgen.com)

Phone: (805) 341-0516

**Selected, Peer-Reviewed Publications (continued)**

- **Honarpour N**, Rose C, Brumbaugh J, Anderson J, Graham B, Sweredoski M, Hess S, Coon JJ, Deshaies RJ. FBXL16 and PP2A-B55 $\alpha$  Comprise a Novel Regulatory Axis Involved in Differentiation of Embryonic Stem Cells Along the FLK1+ Lineage. *Molecular and Cellular Proteomics*. 2014;13:780-91.
- Stein EA, **Honarpour N**, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of a PCSK9 Antibody in Homozygous Familial Hypercholesterolemia. *Circulation*. 2013;128:2113-20.
- Aiyer A.R., **Honarpour N**, Herz J., Srivastava D. Loss of Apaf-1 Leads to Partial Rescue of the HAND2-null Phenotype. *Developmental Biology*. 2005;278:155-162.
- **Honarpour N**, Gilbert SL, Lahn BT, Wang X, Herz J. Apaf-1 Deficiency and Neural Tube Closure Defects are Found in Fog Mice. *PNAS USA*. 2001;98:9683-9687.
- **Honarpour N**, Tabuchi K, Stark JM, Hammer RE, Sudhof TC, Parada LF, Wang X, Richardson JA, Herz J. Embryonic Neuronal Death Due to Neurotrophin and Neurotransmitter Deprivation Occurs Independent of Apaf-1. *Neuroscience*. 2001;106:263-274.
- **Honarpour N**, Du C, Richardson JA, Hammer RE, Wang X, Herz J. Adult Apaf-1 Deficient Mice Exhibit Male Infertility. *Developmental Biology*. 2000;218:248-258.

**Book Chapters:**

- Go NF, **Honarpour,N**, Rigl T. "Chapter 24 – Quantitative Microsphere System Omecamtiv Mecarbil Immunoassay and Omecamtiv Mecarbil Codevelopment." *Companion and Complementary Diagnostics – From Biomarker Discovery To Clinical Implementation*. Edited by Jan Trost Jorgensen. Academic Press. 2019, pp. 445-453.

**Society Memberships:**

American Heart Association

American College of Cardiology

European Society of Cardiology